National Cancer Center

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

• National Cancer Center

  Goyang-si, Gyeonggi-do 10408

  161 vizsgálat

• National Cancer Center

  Gyeonggi-do, Gyeonggi-do 10408

  39 vizsgálat

• National Cancer Center

  Goyang, 10408

  28 vizsgálat

• National Cancer Center - Korea

  Goyang-si, Gyeonggido [Kyonggi-do] 10408

  23 vizsgálat

• National Cancer Center

  Goyang-si Gyeonggi-do, 10408

  14 vizsgálat

• National Cancer Center

  Ilsandong-gu, 10408

  3 vizsgálat

  • NCT06561685A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

  • NCT04306900TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

  • NCT04008797A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

• National Cancer Center

  Seoul, 10408

  3 vizsgálat

  • NCT05254171Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

    Contact: Woo Jin Lee, MD

  • NCT05183984Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

    Contact: Lim Myong Cheol

  • NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    Contact: Myong Cheol Lim, MD, PhD

• Clinical Trial Pharmacy, National Cancer Center

  Goyang-si, Gyeonggi-do 10408

  2 vizsgálat

  • NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  • NCT02684006A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

• National Cancer Center

  Ilsan, Gyeonggi-do 10408

  2 vizsgálat

  • NCT06773845Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria

    Contact: In Joon Lee, MD, PhD

  • NCT06166576Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis

    Contact: In Joon Lee, MD, PhD

• National Cancer Center

  Ilsandong-gu, Goyang-si, Gyeonggi-do 10408

  2 vizsgálat

  • NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

    Contact: Clinical Trial Disclosure & Transparency

  • NCT05580562ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

    Contact: Heon Yoo, MD, PhD

• National Cancer Center (NCC)

  Goyang-si, Gyeonggi-do 10408

  2 vizsgálat

  • NCT04744831Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  • NCT04215978Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors

• National Cancer Center (Site 0702)

  Goyang-si, Kyonggi-do 10408

  2 vizsgálat

  • NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    Contact: Study Coordinator

  • NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

• National Cancer Center (Site 1006)

  Goyang-si, Kyonggi-do 10408

  2 vizsgálat

  • NCT03976362A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

  • NCT03976323Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

• National Cancer Center (Site 1354)

  Goyang-si, Kyonggi-do 10408

  2 vizsgálat

  • NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  • NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

• National Cancer Center (Site 2305)

  Goyang-si, Kyonggi-do 10408

  2 vizsgálat

  • NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    Contact: Study Coordinator

  • NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    Contact: Study Coordinator

• National Cancer Center (Site 5202)

  Goyang-si, Kyonggi-do 10408

  2 vizsgálat

  • NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    Contact: Study Coordinator

  • NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    Contact: Study Coordinator

• Center for Lung Cancer, National Cancer Center

  Goyang-si, 10408

  1 vizsgálat

  • NCT06765109Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

    Contact: Ji-Youn Han, M.D., Ph.D. (principal investigator)

• National Cancer Center

  Gyeongin, 10408

  1 vizsgálat

  • NCT06319820A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

• National Cancer Center

  Ilsandong, Goyang 10408

  1 vizsgálat

  • NCT04063527Phase III Trial of Stage I Ovarian Cancer After Surgery

    Contact: Sang Yoon Park

• National Cancer Center

  Kyeonggi-do

  1 vizsgálat

  • NCT06502743First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer

    Contact: Myoung Cheol Lim

• National Cancer Center

  Seogu, Busan 49201

  1 vizsgálat

  • NCT04306900TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

• National Cancer Center - 3107

  Goyang-si, 10408

  1 vizsgálat

  • NCT05671510ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

• National Cancer Center - Breast Cancer

  Goyang, 10408

  1 vizsgálat

  • NCT06757634Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    Contact: Nadene Zack, MS

• National Cancer Center, Center for Breast Cancer

  Goyang-si, Gyeonggi-do 10408

  1 vizsgálat

  • NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

• National Cancer Center - Center For Prostate Cancer

  Goyang-si, 10408

  1 vizsgálat

  • NCT03592472A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

    Contact: Sophia Paspal, Ph.D.

• National Cancer Center /ID# 125602

  Goyang, Gyeonggido 10408

  1 vizsgálat

  • NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer

• National Cancer Center /ID# 204241

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

• National Cancer Center /ID# 231887

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

• National Cancer Center /ID# 240169

  Goyang, Gyeonggido 10408

  1 vizsgálat

  • NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

• National Cancer Center /ID# 241095

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT03595059A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors

• National Cancer Center /ID# 248938

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

• National Cancer Center /ID# 252290

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

• National Cancer Center /ID# 260663

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT04928846A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

• National Cancer Center /ID# 269481

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

• National Cancer Center /ID# 270453

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

• National Cancer Center /ID# 272265

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

• National Cancer Center /ID# 276283

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

• National Cancer Center /ID# 277353

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

• National Cancer Center /ID# 277434

  Goyang-si, Gyeonggido 10408

  1 vizsgálat

  • NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

• National Cancer Center (Site 0061)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT03829319Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

• National Cancer Center (Site 0176)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)

• National Cancer Center (Site 0196)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

• National Cancer Center (Site 0304)

  Goyang-si, Gyeonggi-do 10408

  1 vizsgálat

  • NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

• National Cancer Center (Site 0314)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

• National Cancer Center (Site 0504)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    Contact: Study Coordinator

• National Cancer Center (Site 0626)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

• National Cancer Center (Site 1002)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT03631784A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

• National Cancer Center (Site 1065)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

• National Cancer Center (Site 1800)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    Contact: Study Coordinator

• National Cancer Center (Site 2004)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

    Contact: Study Coordinator

• National Cancer Center (Site 2505)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT07554339A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

    Contact: Study Coordinator

• National Cancer Center (Site # 2704)

  Goyang-si, 10408

  1 vizsgálat

  • NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Contact: Principal Investigator

• National Cancer Center (Site 2800)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

• National Cancer Center (Site 2902)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

    Contact: Study Coordinator

• National Cancer Center (Site 2905)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

    Contact: Study Coordinator

• National Cancer Center (Site 3306)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

• National Cancer Center (Site 3603)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT07431827MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

    Contact: Study Coordinator

• National Cancer Center (Site 3801)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

    Contact: Study Coordinator

• National Cancer Center (Site 3803)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

• National Cancer Center (Site 4065)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

• National Cancer Center (Site 4202)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

• National Cancer Center (Site 9902)

  Goyang-si, Kyonggi-do 10408

  1 vizsgálat

  • NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

    Contact: Study Coordinator

• National Cancer Center,Substudy-01

  Goyang, 410769

  1 vizsgálat

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• National Cancer Center,Substudy-02

  Goyang, 410769

  1 vizsgálat

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• National Cancer Center,Substudy-03

  Goyang, 410769

  1 vizsgálat

  • NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer

• National Cancer Centre

  Goyang

  1 vizsgálat

  • NCT03133546Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

• National Cancer Centre

  Goyang-si, Gyeonggi-do 10408

  1 vizsgálat

  • NCT04052971To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation